Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the…
<!-- Name:DistributionId Value:8789036 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Nasdaq:SLRX
Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular…
<!-- Name:DistributionId Value:8737683 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical…
Dr. Aundrietta Duncan to discuss mechanism of action and SP-3164 activity in cancer models Company planning to submit an Investigational New Drug application to the U.S. Food and Drug…
Investigators Present Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in…
Patients treated in dose-escalation portion of Phase 1/2 study evaluating seclidemstat in combination with azacitidine 50% overall response rate among eight myelodysplastic syndrome (MDS)…
Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th…
Data showcased novel compound with potential for improved anti-cancer activity over other molecular glues Salarius plans to release additional preclinical results at the American…
Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare…
HOUSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing medicines for patients fighting cancer and…
Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022…
Salarius Successfully Completes SP-3164 Pre-IND Meeting Process with FDA Advancing multiple drug development programs, led by SP-3164 in targeted protein degradation, and seclidemstat in…
Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting…
HOUSTON, May 11, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with…
Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial
HOUSTON, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with…
Salarius Pharmaceuticals and Nationwide Children’s Hospital Announce Poster…
HOUSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with…